Industry Insight
Discovery Technology
Analytical Laboratory Technology
Biopharma
Manufacturing
Delivery Systems
Ingredients, Formulation and Finishing
Bioprocessing
View our other publications with free access to extensive archives
  To print this article:
Existing subscribers please log in:
 
  USER NAME  
  PASSWORD  
   Or select

Or become a subscriber
 
 
 

Fair Play?

Generic pharma companies represent a threat to original drug manufacturers’ profits once a product’s patent expires. The recent trend for product hopping has prompted outrage, but Paul Harris at Pillsbury Winthrop Shaw Pittman wonders what other choices are available.

Paul Harris, Pillsbury Winthrop Shaw Pittman (September 2014)

Keywords: Generic equivalents, Reformulation, Anti-competitive behaviour, Blockbuster drugs

    View full article    |    Back to Industry Insight section




Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPTonline © 2004 The Pharmaceutical Technology Journal | Terms and Conditions | info@iptonline.com | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |